



Rep. La Shawn K. Ford

**Filed: 2/17/2022**

10200HB5318ham001

LRB102 25274 BMS 36515 a

1 AMENDMENT TO HOUSE BILL 5318

2 AMENDMENT NO. \_\_\_\_\_. Amend House Bill 5318 by replacing  
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Insurance Code is amended by  
5 changing Section 356u as follows:

6 (215 ILCS 5/356u)

7 Sec. 356u. Pap tests and prostate cancer screenings  
8 ~~prostate specific antigen tests.~~

9 (a) A group policy of accident and health insurance that  
10 provides coverage for hospital or medical treatment or  
11 services for illness on an expense-incurred basis and is  
12 amended, delivered, issued, or renewed after January 1, 2024  
13 ~~the effective date of this amendatory Act of 1997~~ shall  
14 provide coverage, without imposing a deductible, coinsurance,  
15 copayment, or any other cost-sharing requirement, for all of  
16 the following:

1 (1) An annual cervical smear or Pap smear test for  
2 female insureds.

3 (2) An annual prostate cancer screening ~~digital rectal~~  
4 ~~examination and a prostate-specific antigen test,~~ for male  
5 insureds upon the recommendation of a physician licensed  
6 to practice medicine in all its branches for:

7 (A) asymptomatic men age 50 and over;

8 (B) African-American men age 40 and over; and

9 (C) men age 40 and over with a family history of  
10 prostate cancer.

11 (3) Surveillance tests for ovarian cancer for female  
12 insureds who are at risk for ovarian cancer.

13 (b) This Section shall not apply to agreements, contracts,  
14 or policies that provide coverage for a specified disease or  
15 other limited benefit coverage.

16 (c) This Section does not apply to coverage of prostate  
17 cancer screenings to the extent such coverage would disqualify  
18 a high-deductible health plan from eligibility for a health  
19 savings account pursuant to Section 223 of the Internal  
20 Revenue Code.

21 (d) ~~(e)~~ For the purposes of this Section:

22 "At risk for ovarian cancer" means:

23 (1) having a family history (i) with one or more  
24 first-degree relatives with ovarian cancer, (ii) of  
25 clusters of women relatives with breast cancer, or (iii)  
26 of nonpolyposis colorectal cancer; or

1 (2) testing positive for BRCA1 or BRCA2 mutations.

2 "Prostate cancer screening" means medically viable methods  
3 for the detection and diagnosis of prostate cancer, including  
4 a digital rectal exam and the prostate-specific antigen test  
5 and associated laboratory work. "Prostate cancer screening"  
6 includes medically necessary subsequent follow-up testing as  
7 directed by a health care provider, including, but not limited  
8 to:

9 (1) urinary analysis;

10 (2) serum biomarkers; and

11 (3) medical imaging, including, but not limited to,  
12 magnetic resonance imaging.

13 "Surveillance tests for ovarian cancer" means annual  
14 screening using (i) CA-125 serum tumor marker testing, (ii)  
15 transvaginal ultrasound, (iii) pelvic examination.

16 (Source: P.A. 94-122, eff. 1-1-06.)".